Robert Paull

Co-Founder and Venture Partner, Lux Capital

Paull is Co-Founder and Venture Partner, focusing on healthcare. Robert manages Lux Capital’s investments in Kyruus (healthcare IT), Cala Health (bioelectronics), Cerulean Pharmaceuticals (NASDAQ: CERU – pharmaceutical nanoencapsulation), Magen Biosciences (acquired by PPD – dermatology), Molecular Imprints (acquired by Canon – semiconductor imprint lithography), and Visterra, Inc. (infectious diseases).

Paull was the founding CEO of Harvard Medical School spinout Genocea Biosciences (NASDAQ: GNCA – vaccine discovery) and founding CEO of Johns Hopkins spinout Kala Pharmaceuticals (ophthalmology). Paull was nominated as Biotech CEO of the Year at the World Vaccine Congress and was selected as one of the “100 of the Most Inspiring People” by PharmaVoice Magazine. He is Co-Founder of Lux Research and has served as an advisor to the Bill & Melinda Gates Foundation.

Paull was also a member of Motorola’s Research Visionary Board and has been an invited lecturer or panelist at MIT, Stanford, Yale University, Brown, Memorial Sloan-Kettering Cancer Center, the National Cancer Institute, Georgetown, and the University of Virginia. He has been published in The Journal of Biomedical Materials Research and Nature Biotechnology. Paull graduated from the University of Virginia with a B.S. in Architecture and is a former member of the Regional Selection Committee for UVA’s Jefferson Scholars Foundation.